Choong, Grace M.
Liddell, Savannah
Ferre, Roberto A. Leon
O’Sullivan, Ciara C.
Ruddy, Kathryn J.
Haddad, Tufia C.
Hobday, Timothy J.
Peethambaram, Prema P.
Liu, Minetta C.
Goetz, Matthew P.
Giridhar, Karthik V. http://orcid.org/0000-0003-4640-9197
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1TR002377, KL2 TR002379)
Mayo Clinic (P50 CA116201)
Article History
Received: 27 April 2022
Accepted: 14 August 2022
First Online: 31 August 2022
Declarations
:
: All authors declare no direct conflicts of interests related to material provided in this manuscript. GMC, SL, KJR, TJH, and PPP have no competing interests. RLF–consulting services for Gilead Sciences, AstraZeneca. Honoraria have been paid to the institution for research activities. COS—Research funding from Eli Lilly, Seattle Genetics, Bavarian Nordic, Minneamrita Therapeutics, Biovica, Nfrence Inc, AACRU, and Sermonix Pharmaceuticals. TCH—Research funding from Takeda Oncology for a phase II clinical trial for metastatic breast cancer. MCL—Research support from Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro. MCL also sits on the advisory boards for Astra Zeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax. MPG—Personal fees for CME activities from Research to Practice, Clinical Education Alliance, Medscape, personal fees serving as a panelist for a panel discussion from Total Health Conferencing, and personal fees for serving as a moderator for Curio Science. Consulting fees to institution from AstraZeneca, Biovica, Biotheranostics, Blueprint Medicines, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer, Sanofi Genzyme, and Sermonix. Grant funding to institution from Lilly, Pfizer, and Sermonix. MPG is the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. and receives financial support from the National Cancer Institute under the Mayo Clinic Breast Cancer SPORE (PC50CA116201). KVG—Honoraria to the institution from Novartis. Research funding from Pfizer.